The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,807.50
Ask: 1,808.50
Change: 10.50 (0.58%)
Spread: 1.00 (0.055%)
Open: 1,797.00
High: 1,810.00
Low: 1,792.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Fri, 24th Jun 2016 09:49

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday, following the UK's vote to leave the European Union.
----------
FTSE 100 - WINNERS
----------
Randgold Resources, up 15%, Fresnillo, up 11%. The miners were up on the higher gold price, quoted at USD1,311.39 an ounce compared to USD1,265.12 at the London equities close Thursday. The precious metal reached a 2016 record high earlier Friday at USD1,359.19 an ounce.

GlaxoSmithKline, up 1.1%, Mediclinic International, up 0.8%, AstraZenenca, up 0.3%. Large-cap pharmaceutical companies stand to benefit from a weak pound, as much of their revenue is in dollars and other non-UK or European currencies. Sterling was quoted at USD1.3869 at mid-morning, having touched a low it hasn't seen since 1985 at USD1.3227 earlier Friday. However, Mike Thompson, chief executive officer of the Association of the British Pharmaceutical Industry, said the UK's vote to leave the EU "creates immediate challenges" for the industry, and smaller drug shares were sharply lower, including Tiziana Life Sciences, down 19%, Evgen Pharma, down 16%, and Oxford Pharmascience Group, down 13%.
----------
FTSE 100 - LOSERS
----------
Taylor Wimpey, down 24%, Persimmon, down 24%, Barratt Developments, 21%. "The debate over what the EU referendum means for the outlook for the UK will last much longer than today, but for now we offer the conclusion that the outcome is bad for housebuilders' shares as the combination of slowing GDP, rising longer term rates and political uncertainty is like Kryptonite for that group of shares," said Liberum analyst Charlie Campbell.

Lloyds Banking Group, down 21%, Aviva, down 20%, Barclays, down 19%, Royal Bank of Scotland, down 18%. The financial services companies had been trading particularly higher in the lead up to the vote. In the week prior to the referendum the sector FTSE 350 banking index was up 12%, however on Friday morning index was down 10%.

International Consolidated Airlines Group, down 19%. The British Airways, Aer Lingus and Iberia parent company issued a profit warning for 2016 after the UK vote. "Following the outcome of the referendum, and given current market volatility, while IAG continues to expect a significant increase in operating profit this year, it no longer expects to generate an absolute operating profit increase similar to 2015," IAG said in a statement. EasyJet was down 19%.

ITV, down 18%. The broadcaster was by far the European media stock most exposed to Brexit risk, with 73% of its revenue coming from advertising, according to Societe Generale, which cut its rating on the company to Sell from Hold.
----------
FTSE 250 - WINNERS
----------
Gold miners - Acacia Mining, up 15%, Centamin, up 7.8%, Polymetal International, up 4.8%.
----------
FTSE 250 - LOSERS
----------
Banks - Aldermore Group, down 24%, Virgin Money Holdings, down 22%, Shawbrook Group, down 21%.

Housebuilders - Crest Nicholson Holdings, down 22%, Derwent London, down 22%, Bellway, down 21%, Redrow down 14%.

Recruiters - Hays, down 23%, Page Group, down 18%. Recruitment firms earlier had warned of a slow down in hiring in the run up to the referendum.
----------
MAIN MARKET AND AIM - LOSERS
----------
Proxama, down 43% at 0.429 pence. The marketing and mobile payment solutions company reported a wider pretax loss in 2015, although revenue rose, as it announced it will raise GBP2 million in a share placing. The company said its pretax loss widened to GBP6.1 million in 2015 from GBP5.9 million in 2014, despite revenue multiplying to GBP2.5 million from GBP650,978. Profit was hindered by an increase in administrative expenses to GBP8.6 million from GBP5.8 million, but revenue was boosted by good progress within the digital payments division. Proxama also said it will raise GBP2 million through the placing of 666.7 million shares at 0.3 pence each. Proxama said the placing price represents a discount of approximately 59% to the closing price of 0.725 pence on Thursday, and certain directors of the company have indicated an intention to invest GBP260,000 as part of the placing.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.